AR and posterior cortical atrophy: Erdafitinib (JNJ-42756493),509 a small oral molecule that works against all four FGFR family members, is being tested in a phase 2 clinical study (Table 10) of AR-null and neuroendocrine-null PCa, termed double-negative prostate cancer (DNPC).